Drugs / APL-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05055518 | Aug 2021 → Oct 2028 | — | Apollomics Inc. | Suspended | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-12-22 | Apollomics Inc. | Regulatory APOLLOMICS, INC. RECEIVES CHINA INVESTIGATIONAL NEW DRUG APPROVAL FOR APL-102 TO INITIATE A PHASE 1 STUDY apollomicsinc.com ↗ |
| 2022-12-22 | Apollomics Inc. | Results Apollomics, Inc. Presents Positive Preclinical Data on APL-102, an oral Multi-Kinase Inhibitor with CSF-1R Activity apollomicsinc.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-22 | Apollomics Inc. | APOLLOMICS, INC. RECEIVES CHINA INVESTIGATIONAL NEW DRUG APPROVAL FOR APL-102 TO INITIATE A PHASE 1 STUDY apollomicsinc.com ↗ |
| 2022-12-22 | Apollomics Inc. | Apollomics, Inc. Presents Positive Preclinical Data on APL-102, an oral Multi-Kinase Inhibitor with CSF-1R Activity apollomicsinc.com ↗ |
| 2022-12-22 | Apollomics Inc. | APOLLOMICS, INC. DOSES FIRST PATIENT IN A PHASE I CLINICAL TRIAL OF APL-102 apollomicsinc.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APL-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05055518 ↗ |